Related Experiment Video
Updated: Mar 21, 2026
Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
Published on: May 24, 2024
Outcomes with limus-coated vs. paclitaxel-coated balloons for percutaneous coronary intervention: An updated
Mohamed Saad Sayed1, Mohamed R Abdelraouf2, Ahmed M Kedwany3
1Faculty of Medicine, Beni-Suef University, Beni Suef, Egypt.
Background:
Paclitaxel drug-coated balloons (DCBs) are an established option for treating coronary in-stent restenosis (ISR) and small vessel disease. However, randomized controlled trials (RCTs) comparing limus-DCBs with paclitaxel-DCBs have reported inconsistent findings.
Objectives:
This updated meta-analysis compared clinical and angiographic outcomes of limus- versus paclitaxel-DCBs in patients undergoing percutaneous coronary intervention (PCI).
Methods:
Electronic databases were searched through July 2025 to identify RCTs comparing limus-DCBs with paclitaxel-DCBs in PCI. The primary outcome was target lesion failure (TLF). Summary estimates were generated using a random-effects model. Subgroup analyses were performed based on lesion type and limus agent.
Results:
Ten RCTs, including 1471 patients, were analyzed. At a mean follow-up of 11.7 months, no significant difference was found in TLF (risk ratio [RR] 1.11; 95% confidence interval [CI] 0.84-1.47). Subgroup analyses showed no interaction for de novo lesions versus ISR (Pinteraction = 0.26) or for biolimus- versus sirolimus-DCBs (Pinteraction = 0.32). No significant differences were observed in major adverse cardiac events (RR 1.10; 95% CI 0.86-1.41), target lesion revascularization (RR 1.18; 95% CI 0.88-1.57), cardiac mortality (RR 0.71; 95% CI 0.25-2.04), or target vessel myocardial infarction (RR 0.71; 95% CI 0.30-1.69). Angiographic outcomes-including binary restenosis, late lumen loss, minimal lumen diameter, acute gain, net gain, and diameter stenosis-were also comparable.
Conclusion:
Among patients undergoing DCB-only PCI, there was no statistically significant difference between limus and paclitaxel-DCBs regarding clinical and angiographic outcomes. Larger RCTs with extended follow-up duration are needed to confirm these findings.
